Intriguingly, FOXA1 and BMI1 exhibit opposing roles in modulating the PI3K/Akt pathway: BMI1 activates PI3K/Akt signaling to drive tumor growth and chemoresistance [52], whereas FOXA1 suppresses MND1 to inhibit progression and enhance oxaliplatin sensitivity via the same pathway [41]. This evidence concerns the gene AKT1 and neoplasm.